Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.

Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C.

Onco Targets Ther. 2019 Mar 25;12:2159-2170. doi: 10.2147/OTT.S194745. eCollection 2019.


Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation.

Napoleoni L, Cortellini A, Cannita K, Parisi A, Dal Mas A, Calvisi G, Venditti O, Baldi PL, Cocciolone V, Ricci A, Ficorella C.

Bioengineering (Basel). 2019 Jan 22;6(1). pii: E11. doi: 10.3390/bioengineering6010011.


The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice.

Cortellini A, Cocciolone V, Irelli A, Pavese F, Sidoni T, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Bonfili P, Franzese P, Zugaro L, Verna L, Porzio G, Santini D, Cannita K, Ficorella C.

Oncol Lett. 2018 Dec;16(6):7195-7203. doi: 10.3892/ol.2018.9561. Epub 2018 Oct 10.


Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen.

Cortellini A, Cannita K, Parisi A, Venditti O, Lanfiuti Baldi P, De Berardis B, Vicentini R, Vicentini V, Verna L, Porzio G, Ficorella C.

Oncol Rep. 2018 Aug;40(2):803-812. doi: 10.3892/or.2018.6475. Epub 2018 Jun 6.


Pazopanib and pancreatic toxicity: a case report.

Russano M, Vincenzi B, Venditti O, D'Onofrio L, Ratta R, Guida FM, Tonini G, Santini D.

BMC Res Notes. 2015 May 14;8:196. doi: 10.1186/s13104-015-1154-4.


Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis.

Venditti O, De Lisi D, Caricato M, Caputo D, Capolupo GT, Taffon C, Pagliara E, Battisi S, Frezza AM, Onetti Muda A, Tonini G, Santini D.

BMC Cancer. 2015 Mar 1;15:87. doi: 10.1186/s12885-015-1074-7.


Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?

Santini D, Vincenzi B, Venditti O, Dell'Aquila E, Frezza AM, Silletta M, Guida FM, Grasso RF, Silvestris N, Lanzetta G, Tonini G.

Future Oncol. 2013 Dec;9(12):1809-11. doi: 10.2217/fon.13.170.


Comment and reply on: pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens.

Santini D, Frezza AM, Venditti O, Intagliata S, dell'Aquila E, Guida F, Vincenzi B, Tonini G.

Expert Opin Ther Targets. 2013 Apr;17(4):473-4. doi: 10.1517/14728222.2013.773269. Epub 2013 Feb 28. No abstract available.


'Old' and 'new' drugs for the treatment of cancer pain.

Santini D, Lanzetta G, Dell'Aquila E, Vincenzi B, Venditti O, Russano M, Papapietro N, Denaro V, Tonini G, Ripamonti C.

Expert Opin Pharmacother. 2013 Mar;14(4):425-33. doi: 10.1517/14656566.2013.774375. Review.


Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.

Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Frezza AM, Berti P, Tonini G.

Lancet Oncol. 2012 Oct;13(10):1020-4. doi: 10.1016/S1470-2045(12)70373-X. Epub 2012 Sep 18.


Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.

Vincenzi B, Napolitano A, D'Onofrio L, Frezza AM, Silletta M, Venditti O, Santini D, Tonini G.

Expert Opin Investig Drugs. 2011 Dec;20(12):1685-705. doi: 10.1517/13543784.2011.628984. Epub 2011 Oct 20. Review.


Cetuximab: from bench to bedside.

Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S.

Curr Cancer Drug Targets. 2010 Feb;10(1):80-95. Review.


Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.

Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G.

Oncologist. 2010;15(1):85-92. doi: 10.1634/theoncologist.2009-0143. Epub 2010 Jan 5.


Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.

Vincenzi B, Santini D, Russo A, Spoto C, Venditti O, Gasparro S, Rizzo S, Zobel BB, Caricato M, Valeri S, Coppola R, Tonini G.

Cancer. 2009 Oct 15;115(20):4849-56. doi: 10.1002/cncr.24540.


Interleukin 1beta-511T gene (IL1beta) polymorphism is correlated with gastric cancer in the Caucasian population: results from a meta-analysis.

Vincenzi B, Patti G, Galluzzo S, Pantano F, Venditti O, Santini D, Ruzzo A, Schiavon G, Caraglia M, Marra M, Graziano F, Tonini G.

Oncol Rep. 2008 Nov;20(5):1213-20.


Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.

Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4482-6.

Supplemental Content

Loading ...
Support Center